Analysts Offer Predictions for Zai Lab FY2026 Earnings

Zai Lab Limited (NASDAQ:ZLAB - Free Report) - Cantor Fitzgerald issued their FY2026 earnings estimates for shares of Zai Lab in a research report issued on Monday, June 9th. Cantor Fitzgerald analyst L. Watsek expects that the company will post earnings per share of $1.38 for the year. Cantor Fitzgerald currently has a "Overweight" rating on the stock. The consensus estimate for Zai Lab's current full-year earnings is ($2.58) per share.

Zai Lab (NASDAQ:ZLAB - Get Free Report) last released its earnings results on Thursday, May 8th. The company reported ($0.45) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.50) by $0.05. Zai Lab had a negative return on equity of 36.97% and a negative net margin of 76.14%. The firm had revenue of $106.49 million during the quarter, compared to analysts' expectations of $118.40 million.

Several other research analysts have also commented on ZLAB. JPMorgan Chase & Co. boosted their price objective on shares of Zai Lab from $44.00 to $51.00 and gave the stock an "overweight" rating in a research note on Thursday, March 13th. Scotiabank began coverage on shares of Zai Lab in a research report on Friday, March 7th. They set a "sector outperform" rating and a $55.00 price target on the stock. Finally, Bank of America reiterated a "neutral" rating and issued a $36.10 target price (up previously from $29.00) on shares of Zai Lab in a research report on Monday, March 3rd.

Zai Lab Stock Performance

Zai Lab stock traded up $1.63 during trading hours on Wednesday, hitting $43.03. The company had a trading volume of 1,768,346 shares, compared to its average volume of 893,668. Zai Lab has a 1 year low of $16.01 and a 1 year high of $44.34. The firm has a market cap of $4.75 billion, a P/E ratio of -15.53 and a beta of 0.96. The company has a 50-day moving average price of $31.50 and a two-hundred day moving average price of $30.41.

Insider Buying and Selling

In related news, CFO Yajing Chen sold 9,618 shares of Zai Lab stock in a transaction dated Monday, June 2nd. The stock was sold at an average price of $30.00, for a total transaction of $288,540.00. Following the completion of the sale, the chief financial officer now owns 17,429 shares in the company, valued at approximately $522,870. This trade represents a 35.56% decrease in their position. The transaction was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Also, CEO Ying Du sold 46,389 shares of the company's stock in a transaction dated Wednesday, May 14th. The stock was sold at an average price of $28.09, for a total value of $1,303,067.01. Following the sale, the chief executive officer now owns 479,851 shares of the company's stock, valued at $13,479,014.59. This represents a 8.82% decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold 130,207 shares of company stock worth $3,880,239 in the last quarter. 4.96% of the stock is owned by insiders.

Institutional Investors Weigh In On Zai Lab

Hedge funds have recently added to or reduced their stakes in the stock. GF Fund Management CO. LTD. acquired a new position in shares of Zai Lab in the 4th quarter worth approximately $29,000. Pictet Asset Management Holding SA acquired a new position in shares of Zai Lab during the 4th quarter worth $31,000. Caitong International Asset Management Co. Ltd acquired a new position in shares of Zai Lab during the 1st quarter valued at about $75,000. Barclays PLC boosted its holdings in shares of Zai Lab by 337.6% during the 4th quarter. Barclays PLC now owns 3,702 shares of the company's stock worth $97,000 after buying an additional 2,856 shares during the period. Finally, Advisors Preferred LLC bought a new position in shares of Zai Lab in the first quarter worth about $110,000. 41.65% of the stock is currently owned by institutional investors.

Zai Lab Company Profile

Zai Lab Limited develops and commercializes therapies to treat oncology, autoimmune disorders, infectious diseases, and neuroscience. Its commercial products include Zejula, an orally administered poly polymerase 1/2 inhibitor; Optune, a cancer therapy that uses electric fields tuned to specific frequencies to kill tumor cells; NUZYRA for acute bacterial skin and skin structure infections, and community acquired bacterial pneumonia; Qinlock to treat gastrointestinal stromal tumors, and VYVGART, a human IgG1 antibody fragment for myesthenia gravis.